Ionis Pharmaceuticals, Inc. (IONS)
29.04
+1.73
(+6.33%)
USD |
NASDAQ |
Nov 13, 16:00
28.90
-0.14
(-0.48%)
After-Hours: 19:59
Ionis Pharmaceuticals Net Income (Quarterly) : -109.97M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -109.97M |
| June 30, 2026 | -114.65M |
| March 31, 2026 | -92.53M |
| December 31, 2025 | -229.00M |
| September 30, 2025 | -128.61M |
| June 30, 2025 | 123.55M |
| March 31, 2025 | -146.94M |
| December 31, 2024 | -104.00M |
| September 30, 2024 | -140.48M |
| June 30, 2024 | -66.26M |
| March 31, 2024 | -142.80M |
| December 31, 2023 | -9.00M |
| September 30, 2023 | -147.41M |
| June 30, 2023 | -85.29M |
| March 31, 2023 | -124.32M |
| December 31, 2022 | -52.00M |
| September 30, 2022 | -46.99M |
| June 30, 2022 | -105.14M |
| March 31, 2022 | -65.16M |
| December 31, 2021 | 224.70M |
| September 30, 2021 | -82.47M |
| June 30, 2021 | -80.88M |
| March 31, 2021 | -89.87M |
| December 31, 2020 | -356.00M |
| September 30, 2020 | -36.61M |
| Date | Value |
|---|---|
| June 30, 2020 | -37.56M |
| March 31, 2020 | -49.88M |
| December 31, 2019 | 203.34M |
| September 30, 2019 | 18.43M |
| June 30, 2019 | -10.07M |
| March 31, 2019 | 93.98M |
| December 31, 2018 | 302.69M |
| September 30, 2018 | -20.36M |
| June 30, 2018 | -56.57M |
| March 31, 2018 | -10.81M |
| December 31, 2017 | -3.776M |
| September 30, 2017 | -7.493M |
| June 30, 2017 | -3.085M |
| March 31, 2017 | 8.964M |
| December 31, 2016 | 25.86M |
| September 30, 2016 | 7.351M |
| June 30, 2016 | -56.86M |
| March 31, 2016 | -62.92M |
| December 31, 2015 | -71.43M |
| September 30, 2015 | -35.78M |
| June 30, 2015 | 35.65M |
| March 31, 2015 | -16.72M |
| December 31, 2014 | 31.05M |
| September 30, 2014 | -26.68M |
| June 30, 2014 | -12.08M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 2.167B |
| BridgeBio Pharma, Inc. | -60.50M |
| Biogen, Inc. | -20.60M |
| Ultragenyx Pharmaceutical, Inc. | -118.00M |
| Krystal Biotech, Inc. | 63.07M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 242.72M |
| Total Expenses (Quarterly) | 352.69M |
| EPS Diluted (Quarterly) | -0.6617 |
| Enterprise Value | 4.834B |
| Gross Profit Margin (Quarterly) | 95.39% |
| Profit Margin (Quarterly) | -45.31% |
| Earnings Yield | -11.47% |
| Normalized Earnings Yield | -11.80 |